SCHEMBL7876684

SCHEMBL7876684

CCCC(O)C1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18421848 0.91 SHBG (0.52)
SCHEMBL13212040 0.91 TP53 (0.32)
SCHEMBL11892780 0.90 TP53 (0.50)
SCHEMBL11892781 0.90 TP53 (0.50)
SCHEMBL1665955 0.90 TP53 (0.50)
SCHEMBL12134648 0.90
SCHEMBL887649 0.87 TP53 (0.54)
SCHEMBL12134655 0.87 TP53 (0.54)
SCHEMBL18422051 0.87 LMNA (0.34)
SCHEMBL20240088 0.85 TP53 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612407-B2 Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist BEONE MEDICINES I GMBH (CH) 2026-04-28 US disclosed
CN-113423708-B Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR7 agonists 百济神州有限公司 2025-04-22 CN disclosed
EP-3921319-B1 IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST BEIGENE LTD (KY) 2024-03-06 EP disclosed
US-20230167117-A1 IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST BEONE MEDICINES I GMBH (CH) 2023-06-01 US disclosed
EP-3921319-A1 IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST BeiGene, Ltd. (KY) 2021-12-15 EP disclosed
CN-113423708-A Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR7 agonists 百济神州有限公司 2021-09-21 CN disclosed
WO-2020160710-A1 IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST BEIGENE, LTD. (KY) 2020-08-13 WO disclosed
US-20170008890-A1 SUBSTITUTED 4-AZAINDOLES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2017-01-12 US disclosed
EP-2766368-A1 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES Array Biopharma Inc. (US) 2014-08-20 EP disclosed
US-20140228349-A1 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES ARRAY BIOPHARMA, INC. 2014-08-14 US disclosed
US-8044092-B2 Therapeutic compounds ALLERGAN, INC. (US) 2011-10-25 US disclosed
US-20100317872-A1 THERAPEUTIC COMPOUNDS ALLERGAN, INC. (US) 2010-12-16 US disclosed
WO-2010107384-A1 ASPARTYL PROTEASE INHIBITORS MEDIVIR AB (SE) 2010-09-23 WO disclosed
US-7799821-B2 Therapeutic compounds ALLERGAN, INC. (US) 2010-09-21 US disclosed
US-7674786-B2 Therapeutic β-lactams ALLERGAN, INC. (US) 2010-03-09 US disclosed
WO-2009091764-A2 THERAPEUTIC BETA-LACTAMS ALLERGAN, INC. (US) 2009-07-23 WO disclosed
US-20090186866-A1 THERAPEUTIC BETA-LACTAMS ALLERGAN, INC. 2009-07-23 US disclosed
US-20080113943-A1 Therapeutic Beta-Lactams ALLERGAN, INC. (US) 2008-05-15 US disclosed
EP-0971904-A1 NOVEL 1-AMINO-3 BENZYL URACILS BASF AKTIENGESELLSCHAFT (DE) 2000-01-19 EP disclosed
WO-1998042682-A1 NOVEL 1-AMINO-3 BENZYL URACILS BASF AKTIENGESELLSCHAFT (DE) 1998-10-01 WO disclosed